Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Janux Therapeutics (JANX) Operating Expenses (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Operating Expenses for 6 consecutive years, with $42.4 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses rose 46.1% to $42.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $167.7 million through Dec 2025, up 53.21% year-over-year, with the annual reading at $167.7 million for FY2025, 53.21% up from the prior year.
  • Operating Expenses for Q4 2025 was $42.4 million at Janux Therapeutics, down from $45.3 million in the prior quarter.
  • The five-year high for Operating Expenses was $45.3 million in Q3 2025, with the low at $2.7 million in Q1 2021.
  • Average Operating Expenses over 5 years is $23.5 million, with a median of $21.3 million recorded in 2022.
  • The sharpest move saw Operating Expenses surged 860.35% in 2021, then dropped 11.9% in 2023.
  • Over 5 years, Operating Expenses stood at $15.1 million in 2021, then soared by 39.75% to $21.1 million in 2022, then dropped by 11.9% to $18.6 million in 2023, then surged by 56.05% to $29.0 million in 2024, then skyrocketed by 46.1% to $42.4 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $42.4 million, $45.3 million, and $45.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.